Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total value of DKK 4.0 billionReduce the capital of Genmab and honor our commitments under the Restricted Stock ...

The complaint filed in a Seattle court alleges that Genmab, its subsidiary ProfoundBio – which was acquired last year – and ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Investing.com -- Shares of Genmab (NASDAQ: GMAB) fell 3.8% as the biotech company faces a legal challenge from AbbVie Inc ...

Genmab A/S (Nasdaq: GMAB) announced today that AbbVie Inc. (AbbVie) has filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A/S; ProfoundBio US ...

AbbVie claims that Genmab divulged key trade secrets to support the development of ProfoundBio’s investigational ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

We came across a bullish thesis on Genmab A/S (GMAB) on Substack by Oliver | MMMT Wealth. In this article, we will summarize ...

Danish biotech (Nasdaq: GMAB) on Saturday revealed that US pharma major (AbbVie (NYSE: ABBV) has filed a complaint in the US ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...